New pill targets Leukemia's weak spot in frail patients
NCT ID NCT06930352
Summary
This study is testing an oral medication called ziftomenib for adults with a specific type of acute myeloid leukemia (AML) who are not healthy enough for standard intensive chemotherapy. The drug works by blocking a specific pathway (the menin pathway) that these leukemia cells need to grow. Researchers want to see if taking this pill daily can put the cancer into remission and improve quality of life for these patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.